ST LOUIS — September 11, 2025 — Aegis Digital Health, doing business as SweetSpot, has completed a seed funding round of over $1 million, led by Cultivation Capital in St. Louis. The funds will help scale SweetSpot, currently at $2M annual recurring revenue (ARR), toward a strong position for future funding in mid-2026. This round also fulfills the matching requirement for the $100K Arch Grants Growth Grant, which the company was awarded in a competition in June 2025.
Founded in 2021 as a spinout of BioGenerator, who was their first investor, Aegis Digital Health builds and commercializes solutions for virtual care and remote patient management. In 2022, the company launched SweetSpot, a tech-enabled service addressing critical gaps in diabetes management. Since then, SweetSpot has partnered with endocrinology practices nationwide to support thousands of patients with better, more timely care.
The new capital will support SweetSpot's plans to:
Provide operating funds to sustain the company between now and next year’s Series A
Expand sales and marketing capacity and programs
Launch AI features that enhance customer services and improve internal efficiency
“This funding allows us to meet growing demand from clinics and to accelerate the rollout of new tools that make diabetes data actionable,” said Stephen Von Rump, CEO and Founder of SweetSpot. “Our mission is simple: help providers deliver the right intervention at the right time while making the program operationally and financially effortless for their practices.”
Additional participants in the seed funding round include BioGenerator, Missouri Technology Corporation, and the St. Louis County Port Authority (Helix Fund), along with returning angel investors including several St. Louis Arch Angels and the CGSTL Group. To date, SweetSpot has raised over $4 million.
“SweetSpot has the perfect combination of clinical credibility, clear reimbursement pathways, and a business model that providers are demanding. We’re excited to back the team as they continue to scale nationally,” said Cliff Holekamp, Cofounder & Managing Director at Cultivation Capital.
For more details on SweetSpot, visit www.sweetspot.health.
About SweetSpot
SweetSpot combines a centralized software platform for managing diabetes device data, such as data from CGMs and insulin pumps, with wrap-around clinical support services. SweetSpot’s virtual team of Certified Diabetes Care and Education Specialists (CDCES) performs monthly CGM data reviews and coordinates with providers and patients to facilitate treatment plan changes. By actively managing and remotely reviewing CGM data between patient visits, we ensure patients receive timely treatment adjustments to improve glycemic control and patient outcomes.
Additionally, SweetSpot’s automated capture of reimbursable care events optimizes CPT code utilization, unlocking new revenue streams for practices and making our partnerships both clinically effective and financially profitable.
About Cultivation Capital
Cultivation Capital is an early-stage venture capital firm investing in software technology, life sciences, agriculture technology, and geospatial technology companies. Since its founding in 2012, the firm has invested in over 150 companies and is recognized as one of the most active early-stage investors in the United States. For more information, visit https://cultivationcapital.com.
Media Contact: Joelle Fredman Director of Marketing and Community | SweetSpot jfredman@aegisdigitalhealth.com